Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

Back

Harold C. Smith

Harold C. Smith


University of Rochester.
USA

Biography

Harold C. Smith, Ph.D. is a cell and molecular biologist and tenured full professor in the Department of Biochemistry and Biophysics at the University of Rochester, School of Medicine and Dentistry. As a member of the faculty, Dr. Smith developed and instructs the primary technical training course for undergraduates in the Biochemistry major and runs a research laboratory from which over 130 pier reviewed publications have emerged on biological control mechanisms affecting diseases such as cancer, elevated cholesterol and heart disease and HIV/AIDS. He has led his research field with federal and foundation funding and is a key opinion leader on APOBEC host defense factors. In 2003, Dr. Smith founded OyaGen, Inc based on ground breaking research revealing our innate ability to ward off an infection by HIV for the purpose of developing a novel drug intervention strategy towards an eventual cure for AIDS. His biotech company has unique technology and equipment that has enabled recognition of the Company by Federal, State and the pharmaceutical industry as having taken innovation to a new level with promising achievements that are of great importance and potential to the healthcare industry. OyaGen is located at 77 Ridgeland Rd in Henrietta NY, USA. For more information on Dr. Smith and OyaGen please visit the following webpages: http://en.wikipedia.org/wiki/Harold_Smith_(scientist) http://www.oyageninc.com

Research Interest

Dr. Smith founded OyaGen, Inc based on ground breaking research revealing our innate ability to ward off an infection by HIV for the purpose of developing a novel drug intervention strategy towards an eventual cure for AIDS. His biotech company has unique technology and equipment that has enabled recognition of the Company by Federal, State and the pharmaceutical industry as having taken innovation to a new level with promising achievements that are of great importance and potential to the healthcare industry.